Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Peter Borchmann; Justin Ferdinandus; Gundolf Schneider; Alden Moccia; Richard Greil; Mark Hertzberg; Valdete Schaub; Andreas Hüttmann; Felix Keil; Judith Dierlamm; Mathias Hänel; Urban Novak; Julia Meissner; Andreas Zimmermann; Stephan Mathas; Josée M Zijlstra; Alexander Fossa; Andreas Viardot; Bernd Hertenstein; Sonja Martin; Pratyush Giri; Sebastian Scholl; Max S Topp; Wolfram Jung; Vladan Vucinic; Hans-Joachim Beck; Andrea Kerkhoff; Benjamin Unger; Andreas Rank; Roland Schroers; Christian Meyer Zum Büschenfelde; Maike de Wit; Karolin Trautmann-Grill; Peter Kamper; Daniel Molin; Stefanie Kreissl; Helen Kaul; Bastian von Tresckow; Sven Borchmann; Karolin Behringer; Michael Fuchs; Andreas Rosenwald; Wolfram Klapper; Hans Theodor Eich; Christian Baues; Athanasios Zomas; Michael Hallek; Markus Dietlein; Carsten Kobe; Volker Diehl

doi:10.1016/S0140-6736(24)01315-1

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Peter Borchmann
, Justin Ferdinandus
, Gundolf Schneider
, Alden Moccia
, Richard Greil (Co-author)
, Mark Hertzberg
, Valdete Schaub
, Andreas Hüttmann
, Felix Keil
, Judith Dierlamm
, Mathias Hänel
, Urban Novak
, Julia Meissner
, Andreas Zimmermann
, Stephan Mathas
, Josée M Zijlstra
, Alexander Fossa
, Andreas Viardot
, Bernd Hertenstein
, Sonja Martin

Pratyush Giri, Sebastian Scholl, Max S Topp, Wolfram Jung, Vladan Vucinic, Hans-Joachim Beck, Andrea Kerkhoff, Benjamin Unger, Andreas Rank, Roland Schroers, Christian Meyer Zum Büschenfelde, Maike de Wit, Karolin Trautmann-Grill, Peter Kamper, Daniel Molin, Stefanie Kreissl, Helen Kaul, Bastian von Tresckow, Sven Borchmann, Karolin Behringer, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans Theodor Eich, Christian Baues, Athanasios Zomas, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

Original language	English
Journal	LANCET
Volume	2024
Issue number	404(10450)
DOIs	https://doi.org/10.1016/S0140-6736(24)01315-1
Publication status	E-pub ahead of print - Jul 2024

Access to Document

10.1016/S0140-6736(24)01315-1

Cite this

Borchmann, P., Ferdinandus, J., Schneider, G., Moccia, A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fossa, A., Viardot, A., Hertenstein, B., ... Diehl, V. (2024). Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. LANCET , 2024(404(10450)). Advance online publication. https://doi.org/10.1016/S0140-6736(24)01315-1

Borchmann, Peter ; Ferdinandus, Justin ; Schneider, Gundolf et al. / Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. In: LANCET 2024 ; Vol. 2024, No. 404(10450).

@article{06f6340be33d41318294cfdd47bc8f1f,

title = "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial",

author = "Peter Borchmann and Justin Ferdinandus and Gundolf Schneider and Alden Moccia and Richard Greil and Mark Hertzberg and Valdete Schaub and Andreas H{\"u}ttmann and Felix Keil and Judith Dierlamm and Mathias H{\"a}nel and Urban Novak and Julia Meissner and Andreas Zimmermann and Stephan Mathas and Zijlstra, \{Jos{\'e}e M\} and Alexander Fossa and Andreas Viardot and Bernd Hertenstein and Sonja Martin and Pratyush Giri and Sebastian Scholl and Topp, \{Max S\} and Wolfram Jung and Vladan Vucinic and Hans-Joachim Beck and Andrea Kerkhoff and Benjamin Unger and Andreas Rank and Roland Schroers and \{Meyer Zum B{\"u}schenfelde\}, Christian and \{de Wit\}, Maike and Karolin Trautmann-Grill and Peter Kamper and Daniel Molin and Stefanie Kreissl and Helen Kaul and \{von Tresckow\}, Bastian and Sven Borchmann and Karolin Behringer and Michael Fuchs and Andreas Rosenwald and Wolfram Klapper and Eich, \{Hans Theodor\} and Christian Baues and Athanasios Zomas and Michael Hallek and Markus Dietlein and Carsten Kobe and Volker Diehl",

note = "Greil: 3rd Medical Department, Paracelcus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria; Arbeitsgemeinschaft Medikament{\"o}se Tumortherapie, Salzburg, Austria.",

year = "2024",

month = jul,

doi = "10.1016/S0140-6736(24)01315-1",

language = "English",

volume = "2024",

journal = "LANCET ",

issn = "0140-6736",

publisher = "Elsevier ",

number = "404(10450)",

}

Borchmann, P, Ferdinandus, J, Schneider, G, Moccia, A, Greil, R, Hertzberg, M, Schaub, V, Hüttmann, A, Keil, F, Dierlamm, J, Hänel, M, Novak, U, Meissner, J, Zimmermann, A, Mathas, S, Zijlstra, JM, Fossa, A, Viardot, A, Hertenstein, B, Martin, S, Giri, P, Scholl, S, Topp, MS, Jung, W, Vucinic, V, Beck, H-J, Kerkhoff, A, Unger, B, Rank, A, Schroers, R, Meyer Zum Büschenfelde, C, de Wit, M, Trautmann-Grill, K, Kamper, P, Molin, D, Kreissl, S, Kaul, H, von Tresckow, B, Borchmann, S, Behringer, K, Fuchs, M, Rosenwald, A, Klapper, W, Eich, HT, Baues, C, Zomas, A, Hallek, M, Dietlein, M, Kobe, C & Diehl, V 2024, 'Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial', LANCET , vol. 2024, no. 404(10450). https://doi.org/10.1016/S0140-6736(24)01315-1

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. / Borchmann, Peter; Ferdinandus, Justin; Schneider, Gundolf et al.
In: LANCET , Vol. 2024, No. 404(10450), 07.2024.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

AU - Borchmann, Peter

AU - Ferdinandus, Justin

AU - Schneider, Gundolf

AU - Moccia, Alden

AU - Greil, Richard

AU - Hertzberg, Mark

AU - Schaub, Valdete

AU - Hüttmann, Andreas

AU - Keil, Felix

AU - Dierlamm, Judith

AU - Hänel, Mathias

AU - Novak, Urban

AU - Meissner, Julia

AU - Zimmermann, Andreas

AU - Mathas, Stephan

AU - Zijlstra, Josée M

AU - Fossa, Alexander

AU - Viardot, Andreas

AU - Hertenstein, Bernd

AU - Martin, Sonja

AU - Giri, Pratyush

AU - Scholl, Sebastian

AU - Topp, Max S

AU - Jung, Wolfram

AU - Vucinic, Vladan

AU - Beck, Hans-Joachim

AU - Kerkhoff, Andrea

AU - Unger, Benjamin

AU - Rank, Andreas

AU - Schroers, Roland

AU - Meyer Zum Büschenfelde, Christian

AU - de Wit, Maike

AU - Trautmann-Grill, Karolin

AU - Kamper, Peter

AU - Molin, Daniel

AU - Kreissl, Stefanie

AU - Kaul, Helen

AU - von Tresckow, Bastian

AU - Borchmann, Sven

AU - Behringer, Karolin

AU - Fuchs, Michael

AU - Rosenwald, Andreas

AU - Klapper, Wolfram

AU - Eich, Hans Theodor

AU - Baues, Christian

AU - Zomas, Athanasios

AU - Hallek, Michael

AU - Dietlein, Markus

AU - Kobe, Carsten

AU - Diehl, Volker

N1 - Greil: 3rd Medical Department, Paracelcus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria.

PY - 2024/7

Y1 - 2024/7

U2 - 10.1016/S0140-6736(24)01315-1

DO - 10.1016/S0140-6736(24)01315-1

M3 - Original Article

C2 - 38971175

SN - 0140-6736

VL - 2024

JO - LANCET

JF - LANCET

IS - 404(10450)

ER -

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. LANCET . 2024 Jul;2024(404(10450)). Epub 2024 Jul. doi: 10.1016/S0140-6736(24)01315-1